Vaxart Inc is a biotechnology company focused on developing oral vaccines based on its proprietary platform technology. The company aims to create innovative vaccines that are not only effective but also easy to administer, eliminating the need for needles. Vaxart's research and development primarily targets infectious diseases, with a particular emphasis on creating solutions for viral infections and other public health challenges. Through its unique oral delivery system, Vaxart strives to enhance patient compliance and broaden access to vaccination, ultimately contributing to global health improvement. Read More
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.
Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.
